Abstract

The present invention relates to porous carbon structure comprising one or more sets of porous spherical carbon particles, wherein each of said one or more sets of porous spherical carbon particles has a monomodal, bimodal or multimodal particle diameter distribution, and/or a monomodal, bimodal or multimodal templated pore size distribution, wherein each mode of said particle diameter distribution defines a subset of porous spherical carbon particles within the set, each subset having a particle diameter dispersity (đ) of 1.2 or less, and wherein each mode of the templated pore size distribution defines a subset of porous spherical carbon particles within the set, each subset having a templated pore size dispersity (đ') of 1.2 or less. The invention further relates to methods for producing the porous carbon structures of the invention, electrodes made from such structures and their use in various applications, including among others electrochemical energy storage and conversion.

IPC Classes  ?

• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• H01M 4/00 - Electrodes

Abstract

The present disclosure provides vaccines that include one or more HCMV viral Fc receptors (vFcyRs) or immunogenic fragments thereof and methods related thereto.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The invention relates in a first aspect to a transforming growth factor-β-activated kinase-1 (TAK1) inhibitor for use in the treatment and/or prevention of a neuroinflammatory disorder, wherein the is preferably a T-cell induced microglia-mediated neuroinflammation. The invention relates in another aspect to a method for inhibiting microglia activation in a mammalian subject comprising inhibition of TAK1 which inhibits (reduces severity of) neuroinflammatory disorders, toxicities of cytokine release syndrome (CRS), neurotoxicity and/or neurocognitive defects. In another aspect the present invention relates to an inhibitor of microglial activation for use in the treatment of CAR T ICANS. In a further aspect the present invention relates to a method of treatment of a mammalian subject suffering a neuroinflammatory disorder, the method comprising administering a TAK1 inhibitor to said subject.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/365 - Lactones
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to a method for increasing the productivity of eukaryotic production cells, said production cells expressing one or more protein(s) of interest (POI) during a production phase, comprising the step of irradiating said cells with light having a wavelength or a range of wavelengths within the range of 450 to 500 nm during said production phase.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The disclosure provides methods and compositions for treating HBV. Disclosed is an HBcAg particle, comprising HBV core proteins from at least two different HBV genotypes, and a vaccine vector comprising a nucleotide sequence having ≥90% sequence identity to SEQ ID NO: 5. Disclosed are respective pharmaceutical compositions and their uses in therapy, for medicament manufacture and a vaccination method. Said vaccination method comprises administering to a human (i) a first dose and (ii) a second dose of an HBcAg particle and of an HBsAg, and (iii) a dose of a vaccine vector that expresses a HBsAg from HBV genotype A, a HBcAg from HBV genotype D, a HBsAg having ≥90% sequence identity to SEQ ID NO: 7, a HBcAg having ≥90% sequence identity to SEQ ID NO: 8 or 17, and an RT domain having ≥90% sequence identity to SEQ ID NO: 9.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61P 31/20 - Antivirals for DNA viruses

Abstract

33B-type silicon phthalocyanine including new silicon tribenzophthalocyanine dyes.

IPC Classes  ?

• C09B 47/18 - Obtaining compounds having oxygen atoms directly bound to the phthalocyanine skeleton
• C09B 47/30 - Metal-free phthalocyanines
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to composite polymer particles and thereof derived porous carbon particles with tailored inter- and intraparticle properties. Furthermore, the present invention describes a hard-templating method involving polymerization and self- assembly of a monomer/oligomer/polymer around inorganic template particles for independently controlling the composite polymer particle size for a given template particle size and thereby the pore size and particle size of porous carbon nanoparticles. As a result, particle sizes of porous carbon particles can be generated independently of pore sizes via hard-templating processes.

IPC Classes  ?

• C08G 73/02 - Polyamines
• C01B 32/15 - Nanosized carbon materials
• C08K 3/36 - Silica
• B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• H01M 4/96 - Carbon-based electrodes

Abstract

The recent discovery of CRISPR/Cas9 editing technology has drastically improved the ability to modify the genome of any cell at precise locations. The present invention relates to the use of acetylsalicylic acid, a nonsteroidal anti-inflammatory agent known commercially as "aspirin", to accelerate homologous genome repair, protect against genotoxic injury, and thereby increase the efficiency and efficacy of genome editing in target eukaryotic cells or organisms. The discovery that acetylsalicylic acid ("ASA") is a histone acetylating agent capable of modulating of chromatin structure and accelerating genome repair via HDR represents a significant/ novel advance in the current understanding of the mechanism of ASA. As a clinically safe drug, ASA can be used to enhance and improve precision genome editing in cell culture and in live organisms with minimal toxicities.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 5/0786 - MonocytesMacrophages
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present disclosure provides a method of selecting a hypogammaglobulinemia patient that needs an immunoglobulin replacement therapy (IgG-RT) by analyzing the patient's B cell repertoire. The method can be used before treatment of the patient with IgG-RT. The method may also encompass treatment of the patient. Further provided herein include a diagnostic product on a computer readable medium providing information for the patient selection. B cell repertoire may be measured by the number or abundance of individual antibody clones, by calculating a diversity index value of the antibody clones, by calculating a total frequency of the 10 to 30 most frequent antibody clones, by determining a variable region gene (V region) usage frequency in the antibody clones, optionally wherein the V region gene is selected from the group consisting of IGHV4-30-2 heavy chain V region gene, IGHV4-30-4 heavy chain V region gene, IGHV3-23 gene, IGHV4-34 heavy chain V region gene, and IGHV4-31 heavy chain V region gene; by measuring a percent germline identity by comparing the V or J region in the BCR repertoire against a corresponding germline sequence; and/or by determining the somatic mutation frequency in different regions along the V region.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

The present disclosure relates to a microvalve and a microvalve array comprising one or more such microvalves designed according to the present disclosure. A microvalve comprises a base body with a cavity and at least one first opening and at least one second opening, each opening extending into the cavity, a deflectable membrane, which separates the cavity into a first chamber and a second chamber, an actuating element, which is supported by the base body and which contacts the deflectable membrane and is operable to deflect the membrane to move between at least two positions, wherein the deflectable membrane comprises at least one through-hole extending between the first chamber and the second chamber.

IPC Classes  ?

• F16K 7/14 - Diaphragm cut-off apparatus, e.g. with a member deformed, but not moved bodily, to close the passage with flat, dished, or bowl-shaped diaphragm arranged to be deformed against a flat seat
• F16K 11/20 - Multiple-way valves, e.g. mixing valvesPipe fittings incorporating such valvesArrangement of valves and flow lines specially adapted for mixing fluid with two or more closure members not moving as a unit operated by separate actuating members
• F16K 31/00 - Operating meansReleasing devices
• F16K 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

A system, a method and a computer program product are disclosed. The system is suitable for processing event-evoked physiological signals corresponding to a number of epochs of a trial, each epoch associated with an event involving a subset of a plurality of items. The system comprises a processor system configured to: calculate, a first value based on the epochs associated with a particular item of the plurality of items; calculate a second value based on the epochs not associated with the particular item; and select an item of the plurality of items as an attended-to item associated with the trial, based on the first value and the second value. The system/method/computer program product may have applications in the fields of health care, communications, gaming, control, rehabilitation, monitoring, neuromarketing, clinical assessments, objective assessments of healthy users (e.g. attention), etc. The system can be implemented using a computer or a distributed system such as cloud computing, with a dedicated brain-computer interface device.

IPC Classes  ?

• A61B 5/378 - Visual stimuli
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

The present invention relates to an ultrasonic welding method for connecting a first joining partner to a second joining partner, comprising the steps of A) arranging the two joining partners between a coupling surface of a sonotrode and a coupling surface of a mating tool, B) exerting a force on the two joining partners via at least one of the coupling surfaces in the direction of the other coupling surface, C) exciting the sonotrode with an ultrasonic vibration such that the coupling surface moves at an ultrasonic frequency, D) stopping the exertion of force from step B) and/or stopping the excitation from step C), characterized by the step E) detecting a connection between the first and the second joining partner and by the fact that as soon as a connection is detected in step E), a period of time is started after which the exertion of force from step B) and/or the excitation from step C) are/is stopped.

IPC Classes  ?

• B23K 20/10 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating making use of vibrations, e.g. ultrasonic welding
• B29C 65/08 - Joining of preformed partsApparatus therefor by heating, with or without pressure using ultrasonic vibrations
• B29C 65/64 - Joining a non-plastics element to a plastics element, e.g. by force
• B23K 103/10 - Aluminium or alloys thereof
• B23K 103/12 - Copper or alloys thereof

Abstract

A speech valve for placing and fitting on a tracheostomy cannula, having a throughflow body enclosing a throughflow channel which on one side at one end has a connection for joining to a proximal end of the tracheostomy cannula, a one-way valve located at an end of the throughflow body opposite the connection, and, at a distance along the throughflow channel between the connection and the one-way valve, a valve opening is located which is closable by an overpressure valve. The overpressure valve arrangement has at least one elastically deformable valve flap which, in a first state covers the valve opening provided between the connection structure and the one-way valve on the throughflow body and, at a predefinable overpressure occurring inside the throughflow channel converts, by an overpressure-driven elastic deformation of the valve flap, to a second state, in which it at least partially exposes the valve opening.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61M 16/20 - Valves specially adapted to medical respiratory devices

Abstract

The present invention concerns the diagnosis and assessment of juvenile myelomonocytic leukemia (JMML). In particular, it relates to a method of diagnosing JMML in a subject, the method comprising a) determining the amount of at least one biomarker present on or in hematopoietic stem and progenitor cells (HSPCs) in a biological sample, said at least one biomarker being selected from each of i) group I consisting of: CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD 164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI 1 A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, LPAR6, HLA-DQA1, HLA-DRB5, and CD34, and ii) group II consisting of: IGLL1, BEST1, EREG, SLC5A3, SELK, PRRG3, NINJ1, MGST1, and HLA-G, b) comparing the determined amount of step a) to a reference, and c) diagnosing JMML based on the comparison of step b). Furthermore, the present invention relates to a method of classifying a subject suffering from JMML into a JMML low- or high-risk group. In addition, the present invention concerns use of at least one biomarker present on or in HSPCs in a biological sample for diagnosing JMML into a JMML low- or high-risk group in a subject having or having a risk of developing JMML. Furthermore, the present invention relates to a kit for diagnosing JMML in a subject or classifying a subject suffering from JMML into a JMML low- or high-risk group. Also, the present invention concerns an inhibitory agent that specifically inhibits at least one biomarker selected from the group consisting of CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI 1 A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, LPAR6, HLA-DQA1, HLA-DRB5, CD34, IGLL1, BEST1, EREG, SLC5A3, SELK, PRRG3, NINJ1, MGST1, and HLA-G present on or in hematopoietic stem and progenitor cells (HSPCs) for use in treating and/or preventing JMML. The present invention further relates to a pharmaceutical composition for use in treating and/or preventing JMML comprising at least two inhibitory agents according to the invention. Finally, the present invention envisages a method of treating and/or preventing JMML.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure relates to a method for fabricating a hermetically sealed contact between a vertical electric connection, VIA, through a cover chip (100) and a terminal on a base chip (200). The method comprises the steps of: etching a vertical through hole (110) through the cover chip (100) for forming an etched through hole surface (111, 112) connecting an outside opening (114) and an opposing inside opening (116), the inside opening (116) facing the terminal on the base chip (200); pre-conditioning the etched through hole surface (111, 112) for generating an electrically insulating through hole surface (111a, 112a) and pre-conditioning a contacting region (210) of the base chip (200) for generating an electrically insulating contacting region (210a); depositing a vertical metal layer (111b, 112b) on the electrically insulating through hole surface (111a, 112a) for generating the VIA through the cover chip (100) and depositing a horizontal metal layer (210b) on the electrically insulating contacting region (210a) for generating the terminal on the base chip (200); and thermocompression bonding the vertical metal layer (111b, 112b) of the VIA to the horizontal metal layer (210b) of the terminal for forming a bonded connection, the bonded connection hermetically sealing the contact between the VIA and the terminal.

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate

Abstract

The present invention relates to a micro light-emitting diode (LED), a neural implant comprising at least one such micro LED, and to a method of fabricating a micro LED. A micro LED comprises an active side (106), from which radiation is emitted in operation, and a non-emitting side (108), which extends opposite to the active side, and a lateral region (110) which surrounds the micro LED (100) between the active side (106) and the non-emitting side (108), the micro LED (100) further comprising a first semiconductor region (102), a second semiconductor region (104), an optically active region (103) arranged between the first and second semiconductor regions (102, 104), a first contact metallization (112) for electrically contacting the first semiconductor region (102), and a second contact metallization (118) for electrically contacting the second semiconductor region (104), wherein the second contact metallization (118) is electrically connected to the second semiconductor region (104) in a lateral contact region (111) which is part of the lateral region (110).

IPC Classes  ?

• H01L 33/38 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the electrodes with a particular shape
• A61N 5/06 - Radiation therapy using light
• H01L 33/40 - Materials therefor
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
• H01L 33/30 - Materials of the light emitting region containing only elements of group III and group V of the periodic system
• H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen

Abstract

The invention relates to a method for producing a bone replacement element, wherein an image of a defect to be filled with the bone replacement element is acquired (SI), and at least one region with a specific architecture is defined within the outer contour of the defect (S3). A model is constructed for each of the regions (S4), wherein the model is defined by at least one topological parameter. Each model is constructed by defining a start model which is defined by at least one start value of the at least one topological parameter and the topological parameters are then fitted such that the model matches anatomical parameters within a predefined accuracy. The bone replacement element is then produced according to the model so obtained (S5).

IPC Classes  ?

• A61F 2/28 - Bones
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61F 2/30 - Joints

Abstract

The present invention concerns a mediator probe for the detection of at least one target molecule comprising at least two oligonucleotides. A first oligonucleotide of the mediator probe according to the invention comprises a probe region and a mediator binding region, wherein the probe region has an affinity to a target molecule and/or template molecule, and the mediator binding region has an affinity to at least one mediator. At least one further oligonucleotide of the mediator probe is a mediator which is bound to the first oligonucleotide of the mediator probe via the mediator binding region and has an affinity for at least one detection molecule, wherein the mediator triggers a detectable signal by interaction with the detection molecule after release from the first oligonucleotide of the mediator probe. Furthermore, the present invention concerns a system comprising at least one mediator probe according to the invention and at least one detection molecule, as well as a method for the detection of at least one target molecule.

IPC Classes  ?

• C12Q 1/6823 - Release of bound markers
• C12Q 1/6832 - Enhancement of hybridisation reaction
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present invention generally relates to the field of dye labelled, preferably fluorescent dye labelled, radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof as well as their use in preoperative PET Imaging and Fluorescence-Guided Surgery of cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof comprising a PSMA binding motif Q and a chelator residue A and a dye group Z a linker L1and a linker L2, the compound preferably having the structure Z-L2-A-L1-Q.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 49/00 - Preparations for testing in vivo
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof as well as to the use of said PSMA binding ligand, the PSMA binding ligand comprising a PSMA binding motif Q and a chelator residue A linked via at least one linker LAQii.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61P 35/00 - Antineoplastic agents

Abstract

A device for particle isolation comprises a reservoir to contain a liquid including particles and a channel with an inlet and an outlet. The inlet is configured to be fluidically coupled to the reservoir containing the liquid including particles. The device comprises further a pressure generator configured to generate a pressure gradient in the channel by which liquid including a single particle is aspirated from the reservoir through the inlet of the channel against the force of gravity and to cause liquid to be output through the outlet of the channel. Additionally, the device comprises an actuator configured to cause a relative movement between the particles and the inlet of the channel so as to bring a single particle in a vicinity of the inlet to be aspirated through the inlet.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 1/26 - Inoculator or sampler
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present disclosure relates to methods for treating giant cell arteritis (GCA), using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating GCA patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

IPC Classes  ?

• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof comprising a PSMA binding motif Q and a chelator residue A linked via at least one linker LAQ, the linker comprising at least one N-alkylated, preferably N-methylated amino acid.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Abstract

The present invention generally relates to the field of dye labelled, preferably fluorescent dye labelled, radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof as well as their use in preoperative PET Imaging and Fluorescence-Guided Surgery of cancers, especially prostate cancer, and metastases thereof.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

A description is given of a medical instrument for intubating a patient with an endotracheal tube, ETT for short, enclosing a hollow channel, and also with a guiding rod, which is arranged along the hollow channel, is plastically deformable at least in an axial portion and has a distal rod end and a proximal rod end, attached to the distal rod end of which guiding rod is a bidirectionally deformable guiding element, which has a distal element end and a proximal element end, the proximal element end of the guiding rod element being joined to the distal rod end and the guiding element being connected to a control means. The invention is distinguished by the fact that an operating unit is attached to the proximal rod end of the guiding rod and has an actuator, which is connected to the control means, and also has a push-pull mechanism, which is securely in operative connection with the ETT in a releasable manner and by which the ETT can be moved along the guiding rod, and that, when intubing the ETT together with the guiding rod arranged in the hollow channel of the ETT along with the bidirectionally deformable guiding element attached thereto, the distal end of the ETT finishes with the distal element end or the proximal element end merely projects in a dome-like manner beyond the distal end of the ETT.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61B 1/005 - Flexible endoscopes
• A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments

Abstract

The present invention relates to a use of a labeling compound having a chemical structure of formula (I): (A)-x1-(B)-x2-(C), wherein (A) is at least one motif specifically binding to cell membranes of cancer cells; (B) at least one chelator moiety; (C) a dye moiety; x1 is a spacer covalently connecting (A) and (B); x2 is a spacer or a chemical single bond connecting (B) and (C), or a pharmaceutically acceptable salt thereof, as a labeling agent for detecting cancerous tissue in a subject, said use comprising administration of a labeling dose of said labeling compound to said subject; and to compounds for use, and methods related thereto.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 51/08 - Peptides, e.g. proteins
• A61K 51/04 - Organic compounds

Abstract

The invention relates to a method for detecting at least one target nucleic acid sequence by means of a method for detecting at least one target nucleic acid sequence, said method comprising the steps of: i. providing at least one target-sequence-unspecific modular reporter complex comprising at least one marker, and at least two oligonucleotides, namely i. a base strand comprising 1. at least one mediator binding site, and 2. at least one signal initiation oligo binding site, ii. at least one signal initiation oligo, the signal initiation oligo binding site of the base strand and the at least one signal initiation oligo optionally being hybridised to one another but not covalently bonded and together forming a signal complex; j. providing at least one mediator probe, the mediator probe comprising an oligonucleotide having at least one probe sequence and at least one mediator sequence, the at least one probe sequence having an affinity for at least one target nucleic acid sequence, and the at least one mediator sequence having an affinity for at least one mediator binding site on the base strand of the at least one target-sequence-unspecific modular reporter complex; k. PCR amplification of at least one nucleic acid sequence; l. binding a probe sequence of at least one mediator probe to at least one target nucleic acid sequence; m. using a PCR polymerase to cleave the probe sequence of the at least one mediator probe that is bound to the at least one target nucleic acid sequence, the mediator sequence being released; n. binding at least one released mediator sequence to a mediator binding site of the at least one target-sequence-unspecific modular reporter complex; o. using a PCR polymerase to extend the sequence of at least one mediator sequence that is bound to a mediator binding site, the binding being broken or prevented by hybridising the at least one signal initiation oligo binding site and the at least one signal initiation oligo, thereby initiating a signal change; p. detecting at least one signal change as evidence of the at least one target nucleic acid sequence.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/6823 - Release of bound markers

Abstract

The invention relates to a method for detecting at least one target nucleic acid sequence by means of a mediator probe and at least one target-sequence-unspecific modular reporter complex, wherein the released mediator sequence binds to a mediator binding site of the target-sequence-unspecific modular reporter complex, and is extended. A signal change is initiated and detected. The invention also relates to a kit for carrying out this method.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/6823 - Release of bound markers

Goods & Services

Decoration and art materials and media; Printed matter, and stationery and educational supplies; Filtering materials of paper; Adhesives for stationery or household purposes; Works of art and figurines of paper and cardboard, and architects' models; Paper and cardboard; Bags and articles for packaging, wrapping and storage, of paper, cardboard or plastics; Drawing instruments; Paintbrushes; Bookbinding apparatus and machines [office equipment]; Binding materials for books and papers; Plantable seed paper [stationery]; Paper tissues; Drip mats of cardboard; Napkins made of paper for household use; Towels of paper; Mats of card for beer glasses. Tableware, cookware and containers; Articles for the care of clothing and footwear; Household utensils for cleaning, brushes and brush-making materials; Cosmetic, hygiene and beauty care utensils; Statues, figurines, plaques and works of art, made of materials such as porcelain, terra-cotta or glass, included in the class; Unworked and semi-worked glass, not specified for use; Combs; Sponges. Filtering materials of textile; Fabrics; Textile goods, and substitutes for textile goods. Clothing; Headgear; Footwear; Parts of clothing, footwear and headgear. Education, entertainment and sport services; Publishing, reporting, and writing of texts; Ticket reservation and booking services for education, entertainment and sports activities and events; Translation and interpretation. Science and technology services; Testing, authentication and quality control; IT services; Design services.

Goods & Services

Decoration and art materials and media; Printed matter, and stationery and educational supplies; Filtering materials of paper; Adhesives for stationery or household purposes; Works of art and figurines of paper and cardboard, and architects' models; Paper and cardboard; Bags and articles for packaging, wrapping and storage, of paper, cardboard or plastics; Drawing instruments; Paintbrushes; Bookbinding apparatus and machines [office equipment]; Binding materials for books and papers; Plantable seed paper [stationery]; Paper tissues; Drip mats of cardboard; Napkins made of paper for household use; Towels of paper; Mats of card for beer glasses. Tableware, cookware and containers; Articles for the care of clothing and footwear; Household utensils for cleaning, brushes and brush-making materials; Cosmetic, hygiene and beauty care utensils; Statues, figurines, plaques and works of art, made of materials such as porcelain, terra-cotta or glass, included in the class; Unworked and semi-worked glass, not specified for use; Combs; Sponges. Filtering materials of textile; Fabrics; Textile goods, and substitutes for textile goods. Clothing; Headgear; Footwear; Parts of clothing, footwear and headgear. Education, entertainment and sport services; Publishing, reporting, and writing of texts; Ticket reservation and booking services for education, entertainment and sports activities and events; Translation and interpretation. Science and technology services; Testing, authentication and quality control; IT services; Design services.

Abstract

in vitro in vitro method of diagnosing prostate cancer (PCa) and/or a stage thereof in a subject suspected to or known to suffer from PCa, comprising the steps as disclosed herein; (ii) the use of a characteristic of extracellular vesicles (EVs) in a method of diagnosing cancer and/or a stage thereof, wherein the characteristic of the EVs is selected from the group consisting of the size, the density, the origin and combinations thereof; and (iii) a method of establishing a method of diagnosing cancer and/or a stage thereof, wherein the method of establishing comprises a step of analyzing a characteristic of extracellular vesicles (EVs), wherein the characteristic of the EVs is selected from the group consisting of the size, the density, the origin, and combinations thereof.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a polycondensation method for preparing SH- terminated polymers having at least two terminal SH-groups and comprising sulfur-carbon-sulfur linkages in its polymer backbone, wherein the method comprises a step of reacting at least at least one organic constituent a1 comprising at least one carbonyl group with at least one organic constituent a2 comprising at least two thiol groups, wherein constituent(s) a1 is/are selected from aldehydes having at least one aldehyde group, O-acetals of these aldehydes, ketones having at least one keto group, and mixtures thereof, wherein the two sulfur atoms of the at least two thiol groups of constituent(s) a2 are separated from each other by a linker moiety L having a chain of at least four atoms, and wherein the molar ratio r of constituent(s) a1 and a2 to each other is <1, polymers obtainable by this method, a 2K sealing system comprising such polymers in one of its components, a sealant composition obtainable therefrom, a method of sealing a substrate by making use of said sealant composition, and to a sealed substrate obtainable by this method.

IPC Classes  ?

• C08G 75/10 - Polythioethers from sulfur or sulfur-containing compounds and aldehydes or ketones
• C08G 16/02 - Condensation polymers of aldehydes or ketones with monomers not provided for in the groups of aldehydes
• C08L 61/00 - Compositions of condensation polymers of aldehydes or ketonesCompositions of derivatives of such polymers

Abstract

The present application refers to a method of preventing or reducing metastasis of tumor cells, senescence, differentiation or inflammation wherein the caspase-activated DNAse which induces strand breaks in the genomic DNA of cells causing changes of the behavior of the cell involving aggressive growth, senescence, differentiation and metastasis and/or inflammation is inactivated.

IPC Classes  ?

• A61P 35/04 - Antineoplastic agents specific for metastasis
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• A61P 37/02 - Immunomodulators
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)

Abstract

The invention relates to a dual catheter arrangement for reperfusion of an ischemic tissue region via a coronary vessel, comprising a primary balloon catheter (1) having a lumen (3) for inflation and deflation of a primary balloon (4) disposed at a distal region of the primary balloon catheter, and at least two separate lumens (6, 7) both extending throughout the primary balloon catheter and open at a distal end of the primary balloon catheter, and a secondary balloon catheter (2) having a lumen (12) for inflation and deflation of a secondary balloon disposed at a distal region of the secondary balloon catheter and an irrigation lumen (15) opening at a distal end of the secondary balloon catheter, which is arranged slidable within one of the lumens of the primary balloon catheter to achieve a working position in which the secondary balloon catheter continues completely through the lumen of the primary balloon catheter and extends distally beyond the primary balloon catheter. Further a system for reperfusion of an ischemic tissue region via a coronary vessel is described comprising the dual catheter arrangement.

IPC Classes  ?

• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to the use of a GluN2D inhibitor or a mGluR2 inhibitor in the treatment or relapse prevention of a depressive episode. Vectors encoding some of these inhibitors are also provided for use in the relapse prevention or treatment of depressive episodes. Also provided are pharmaceutical compositions comprising these inhibitors, preferably for use in the relapse prevention or treatment of a depressive episode.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/24 - Antidepressants

Abstract

The present invention relates to the use of a GluN2D inhibitor or a mGluR2 inhibitor in the treatment or relapse prevention of a depressive episode. Vectors encoding some of these inhibitors are also provided for use in the relapse prevention or treatment of depressive episodes. Also provided are pharmaceutical compositions comprising these inhibitors, preferably for use in the relapse prevention or treatment of a depressive episode.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 25/24 - Antidepressants
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The invention relates to a computer-assisted method, a system and a computer-program product for assisting with preoperative planning for introducing a dental implant in a jaw of a patient. On the basis of a provided digital 3D surface reproduction, e.g. a digital plaster model, of at least part of the available dental crowns and/or the oral mucosa of the patient and statistical parametric 3D shape models (SSM), a tooth axis representation, a tooth crown representation and/or an implantation axis representation is generated. This takes place on the basis of the digital 3D surface reproduction and the corresponding statistical parametric 3D shape model. In addition, a corresponding statistical parametric 3D shape model can also be generated by means of the method, system and computer-program product. In order to check the plausibility, the determined representations for the tooth axis, tooth crown and/or implantation axis can be reproduced in an additionally taken 2D X-ray image, e.g. an orthopantomogram.

IPC Classes  ?

• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 17/17 - Guides for drills
• A61C 7/00 - Orthodontics, i.e. obtaining or maintaining the desired position of teeth, e.g. by straightening, evening, regulating, separating, or by correcting malocclusions
• B33Y 80/00 - Products made by additive manufacturing

Abstract

in vitroin vitro plant cell reprogramming towards plant embryogenesis or microcallus formation for further plant regeneration. The present invention also relates to a method to promote this process comprising culturing an isolated plant material with at least one PDE inhibitor, preferably mammalian PDE inhibitor.

IPC Classes  ?

• A01H 4/00 - Plant reproduction by tissue culture techniques

Abstract

The present invention relates to peptides, antigen binding proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, especially of fibrolamellar hepatocellular carcinoma (FL-HCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes and recombinant T-cell receptors that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to peptides, antigen binding proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, especially of fibrolamellar hepatocellular carcinoma (FL-HCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes and recombinant T-cell receptors that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons

Abstract

The invention relates to a robotic system (10) for wound cleaning, comprising a robotic arm (12), on which a nozzle (14) is attached for dispensing a cleaning fluid, a control device for controlling the robotic arm so that determined positions on the wound surface are specifically cleaned by the nozzle (14), at least one sensor for detecting the quality of the cleaning result, a control system for controlling positions on the wound surface where the quality of the cleaning has not reached a desired threshold value.

IPC Classes  ?

• A61M 3/02 - EnemataIrrigators
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 17/3203 - Fluid jet cutting instruments
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 34/32 - Surgical robots operating autonomously
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

59 Abstract The invention relates to methods for determining whether a subject is a responder or a non- responder to breast cancer therapy, in particular neoadjuvant breast cancer therapy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure relates to methods and composition for treating or decreasing the rate of development of cognitive impairment, a neurodegen erative disease, or neuronal dysfunction in a. subject in need thereof. The methods include administration to the subject of a gut barrier function enhancer and/or an agent for reducing or eliminating gut microbiota dysfunction. The disclosure also provides methods for identifying such a subject.

IPC Classes  ?

• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 38/46 - Hydrolases (3)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A sensor array comprises a base for providing a probe signal and a plurality of modular recording sites. Each modular recording site of the plurality of modular recording sites is configured for receiving a signal and for converting the signal into a digital sensor signal using an in-situ analog-to-digital converter. Additionally, the sensor array comprises a data compression unit configured for reducing a data rate of the digital sensor signal obtained by a modular recording site of the plurality of modular recording sites. The base is configured to provide the probe signal based on digital sensor signals provided by the plurality of modular recording sites.

IPC Classes  ?

• A61B 5/262 - Needle electrodes
• A61B 5/293 - Invasive
• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present disclosure relates to methods and composition for treating or decreasing the rate of development of cognitive impairment, a neurodegen erative disease, or neuronal dysfunction in a. subject in need thereof. The methods include administration to the subject of a gut barrier function enhancer and/or an agent for reducing or eliminating gut microbiota dysfunction. The disclosure also provides methods for identifying such a subject.

IPC Classes  ?

• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 38/46 - Hydrolases (3)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A polyolefin composition (I) having low density and improved mechanical properties comprising: (A) 15-80% by weight of an heterophasic polymer composition comprising: (a) 50-80% by weight of a propylene polymer, and (b) 20-50% by weight of a copolymer of ethylene and at least one alpha-olefin; (B) 20-85% by weight of a polyethylene composition comprising: (i) 25-85% by weight of a polyethylene component having a weight average molecular weight Mw(i), measured by Gel Permeation Chromatography, equal to or higher than 1,000,000 g/mol; (ii) 10-65% by weight of a polyethylene component having a weight average molecular weight Mw(ii), measured by Gel Permeation Chromatography, equal to or lower than 5,000 g/mol, wherein the polyethylene composition (B) comprises at least 70% by weight of (i)+(ii) and the amounts of (i) and (ii) are based on the total weight of the polyethylene composition (B), the total weight being 100%, and wherein the amounts of components (A) and (B) are based on the total weight of (A)+(B).

IPC Classes  ?

• B33Y 80/00 - Products made by additive manufacturing
• C08L 23/06 - Polyethene
• C08L 23/12 - Polypropene

Abstract

SpecEnRRRR RMSSDrelRRrelRR relRR ).

IPC Classes  ?

• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

A coated container having reduced nonspecific adsorption of nonspecific targets can have an interior volume surrounded by one or more walls having one or more interior surfaces, and a coating comprising a spray-coated hydrogel layer surface attached to the one or more interior surfaces, the spray-coated hydrogel having surface roughness with surface features with an average features height of less than 20 nm.

IPC Classes  ?

• C09D 5/16 - Anti-fouling paintsUnderwater paints

Abstract

The present invention relates to a compound according to formula (I) or a salt, solvate and/or a hydrate thereof, wherein said compound inhibits a cysteine protease, for use in the treatment and prevention of an inflammatory and/or other fibrotic lung disease, wherein said compound is administered by inhalation as a pharmaceutical composition, preferably comprising alcohol as a carrier.

IPC Classes  ?

• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention relates to compositions comprising modified lignin and modified cellulose which are suitable for use in additive manufacturing (e.g. 3D printing), in particular for direct ink writing (DIW). In particular, the invention relates to a composition suitable for direct ink writing, comprising a) a functional ether of lignin, b) a functional ether of cellulose, and c) a solvent comprising an aliphatic alcohol and optionally water. The content of the functional ether of lignin in the composition is at least 25 wt.% based on the combined weights of functional ether of lignin and functional ether of cellulose.

IPC Classes  ?

• C08L 1/28 - Alkyl ethers
• C08K 5/05 - AlcoholsMetal alcoholates
• C08L 97/00 - Compositions of lignin-containing materials
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials

Abstract

Provided is a method of treating a psychiatric disorder and/or blood pressure disorder in a subject in need thereof. The method includes implanting one or more leads into the subject, wherein each of the one or more leads comprises a plurality of electrodes; generating an electrical signal; generating an electrical field that is substantially directional and substantially focused; and delivering the electrical field to a superolateral branch in a medial forebrain bundle of the subject via at least one of the plurality of electrodes. Provided are also an implantable pulse generator configured to deliver the corresponding electrical field via respective leads and electrodes.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

A process for the manufacture of a non-isocyanate polyurethane (NIPU) composition by transesterification of a condensed tannin with a carbonate or a carbonate precursor followed by the reaction with a hardener selected from diamines, triamines, polyamines and mixtures thereof and products and compositions obtained thereby.

IPC Classes  ?

• C08G 71/04 - Polyurethanes
• C09J 175/12 - Polyurethanes from compounds containing nitrogen and active hydrogen, the nitrogen atom not being part of an isocyanate group
• C08L 75/12 - Polyurethanes from compounds containing nitrogen and active hydrogen, the nitrogen atom not being part of an isocyanate group

Abstract

The present invention relates to novel specific small molecule inhibitors that block KMT9 methyltransferase activity. In particular, the present invention is concerned with a compound of formula (I) wherein X1, X2, X3, X4, R1, R2, R3, R5, R6and L are as defined herein. Further, the present invention is concerned with a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I). The present invention also relates to a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use in medicine. Yet further, the present invention is concerned with a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use as inhibitor of KMT9. Finally, the present invention is concerned with a compound of formula (I), wherein X1, X2, X3, X4, R1, R2, R3, R5, R6 and L are as defined herein, for use in the treatment of cancer selected from the group as defined herein.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07H 19/14 - Pyrrolo-pyrimidine radicals
• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a method for removing the chorion using expansible forceps comprising at least three tips, which are present at the ends of forceps arms. In the method, the chorion is first of all punctured at the at least three points by means of the tips, and then the forceps arms are expanded such that an opening, preferably a polygonal opening, forms in the chorion between the at least three points, from which opening the embryo can emerge. In a further aspect, the invention relates to expansible forceps for performing the method, and to a system comprising expansible forceps and a drive, which is configured for automated performance of the puncturing and opening of the chorion. In preferred embodiments, the method is used to dechorionate a large number of embryos in a high-throughput process, preferably for automated testing of the action of substances on embryos.

IPC Classes  ?

• A61B 17/30 - Surgical pincettes, i.e. surgical tweezers
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present application relates to antibodies which bind to the extracellular domain of an Fc-gamma-binding glycoprotein gp34 and gp68 of human cytomegalovirus and their use in the treatment or prevention of a HCMV infection.

IPC Classes  ?

• A61P 31/20 - Antivirals for DNA viruses
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Hyper-lgE syndrome (HIES). In particular, the present invention provides means and methods for genetically modifying HSCs or T-cells involving gene editing reagents, such as TALE-nucleases, that specifically target an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides populations of engineered HSCs or T-cells which comprise cells comprising an exogenous polynucleotide sequence comprising at least a partial or complete sequence of a functional STATS gene, said exogenous polynucleotide sequence being integrated in an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), resulting in the expression of a functional STATS polypeptide. The present invention further provides pharmaceutical compositions comprising the cell populations of the invention, and their use in gene therapy for the treatment of Hyper-lgE syndrome (HIES).

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Severe Combined Immunodeficiency (SCID) related to RAG1. Particularly, the present invention pertains to the treatment of RAG1 deficiency in long-term repopulating hematopoietic stem cells (HSCs). The present invention provides means and methods for genetically modifying HSCs involving gene editing reagents, such as TALE-nucleases, that specifically target a non-functional endogenous RAG1 gene, comprising at least one mutation causing Severe Combined Immunodeficiency (SCID), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides engineered RAG1-edited HSCs comprising an exogenous sequence comprising a nucleic acid sequence encoding a functional RAG1 protein which is integrated in said HSCs' genome into a non-functional RAG1 endogenous locus, resulting in the expression of a functional RAG1 polypeptide. The present invention further provides populations of cells comprising said engineered HSCs, pharmaceutical compositions comprising said engineered HSCs or populations of cells, as well as their use in gene therapy for the treatment of Severe Combined Immunodeficiency (SCID) related to RAG1.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Hyper-lgE syndrome (HIES). In particular, the present invention provides means and methods for genetically modifying HSCs or T-cells involving gene editing reagents, such as TALE-nucleases, that specifically target an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides populations of engineered HSCs or T-cells which comprise cells comprising an exogenous polynucleotide sequence comprising at least a partial or complete sequence of a functional STATS gene, said exogenous polynucleotide sequence being integrated in an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), resulting in the expression of a functional STATS polypeptide. The present invention further provides pharmaceutical compositions comprising the cell populations of the invention, and their use in gene therapy for the treatment of Hyper-lgE syndrome (HIES).

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Severe Combined Immunodeficiency (SCID) related to RAG1. Particularly, the present invention pertains to the treatment of RAG1 deficiency in long-term repopulating hematopoietic stem cells (HSCs). The present invention provides means and methods for genetically modifying HSCs involving gene editing reagents, such as TALE-nucleases, that specifically target a non-functional endogenous RAG1 gene, comprising at least one mutation causing Severe Combined Immunodeficiency (SCID), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides engineered RAG1-edited HSCs comprising an exogenous sequence comprising a nucleic acid sequence encoding a functional RAG1 protein which is integrated in said HSCs' genome into a non-functional RAG1 endogenous locus, resulting in the expression of a functional RAG1 polypeptide. The present invention further provides populations of cells comprising said engineered HSCs, pharmaceutical compositions comprising said engineered HSCs or populations of cells, as well as their use in gene therapy for the treatment of Severe Combined Immunodeficiency (SCID) related to RAG1.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention relates to an improved method for determining the activity of a betacoronavirus papain-like protease (PLpro) using a peptide substrate, wherein said peptide substrate comprises at least one basic amino acid in positions P1 and/or P1'. The present invention furthermore relates to a method for identifying a modulator of the activity of a betacoronavirus PLpro using a substrate as above, and relates to modulators of the activity of PLpro as identifies, as well as uses thereof against betacoronaviral infection and disease.

IPC Classes  ?

• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

The present invention relates to a device and method for shifting a fluid within a fluid channel. The device comprising: - a fluid channel (20) comprising at least one chamber (15), each chamber (15) being filled with a fluid (12) comprising an electrolyte and having at least two inlets (17), wherein each inlet (17) has a cross-section which is smaller than a cross-section of the at least one chamber (15); - a sealing control element (13) being enclosed in the fluid (12) of the fluid channel (20) for sealing the at least one chamber (15) and controlling a shift of the fluid (12) within the fluid channel (20) in response to a control signal (30); and - at least one pair of electrodes (8) arranged such that the electrodes (8) are in fluidic contact with the at least one chamber (15) for causing, in response to the control signal (30), an electrocapillary force acting on the sealing control element (13); wherein the sealing control element (13) has a surface tension which is higher than a surface tension of the fluid (12), such that in the absence of the control signal (30) at least a portion of the sealing control element (13) is trapped in one of the at least one chamber (15) due to an intrinsic capillary force, thereby sealing said one of the at least one chamber (15).

IPC Classes  ?

• G09B 21/00 - Teaching, or communicating with, the blind, deaf or mute

Abstract

The present invention relates to a device and method for shifting a fluid within a fluid channel. The device comprising: - a fluid channel (20) comprising at least one chamber (15), each chamber (15) being filled with a fluid (12) comprising an electrolyte and having at least two inlets (17), wherein each inlet (17) has a cross-section which is smaller than a cross-section of the at least one chamber (15); - a sealing control element (13) being enclosed in the fluid (12) of the fluid channel (20) for sealing the at least one chamber (15) and controlling a shift of the fluid (12) within the fluid channel (20) in response to a control signal (30); and - at least one pair of electrodes (8) arranged such that the electrodes (8) are in fluidic contact with the at least one chamber (15) for causing, in response to the control signal (30), an electrocapillary force acting on the sealing control element (13); wherein the sealing control element (13) has a surface tension which is higher than a surface tension of the fluid (12), such that in the absence of the control signal (30) at least a portion of the sealing control element (13) is trapped in one of the at least one chamber (15) due to an intrinsic capillary force, thereby sealing said one of the at least one chamber (15).

IPC Classes  ?

• G09B 21/00 - Teaching, or communicating with, the blind, deaf or mute

Abstract

An arrangement in the manner of a speech valve for placing and fitting on a tracheostomy cannula is described, having a through-flow body which encloses a through-flow channel and which on one side at one end has a suitably designed connection structure for joining to a proximal end of the tracheostomy cannula, a one-way valve being arranged at that end of the through-flow body opposite the connection structure along the through-flow channel, and, at a distance along the through-flow channel between the connection structure and the one-way valve, there being arranged, a valve opening that is closable by an overpressure valve arrangement. The invention is characterized in that the overpressure valve arrangement has at least one elastically deformable valve flap which, in a first state, is able to cover the valve opening provided between the connection structure and the one-way valve on the through-flow body and, at a predefinable overpressure inside the through-flow channel, is convertible, by an overpressure-driven elastic deformation of the valve flap, to a second state, in which it at least partially frees the valve opening. Alternatively or in combination, a signal generator is arranged directly or indirectly at the overpressure valve arrangement, or downstream of the overpressure valve arrangement, and generates a signal in the event of overpressure-driven opening of the overpressure valve arrangement.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61M 16/10 - Preparation of respiratory gases or vapours

Abstract

in vitroin vitro or not for use in methods for treatment of the human or animal body, respectively.

IPC Classes  ?

• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure relates to functionalized amino compounds that can provide inhibitors of C-reactive protein (CRP). The present disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of CRP associated diseases, disorders or conditions, and particularly the treatment of inflammation associated with pro-inflammatory effects of CRP, and to related uses.

IPC Classes  ?

• C07F 9/38 - Phosphonic acids [R—P(:O)(OH)2]Thiophosphonic acids
• C07C 309/14 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
• C07C 229/14 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 31/66 - Phosphorus compounds
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids

Abstract

The present disclosure refers to the use of a film or sheet comprising a polymer blend obtained by melt blending a mixture comprising: (A) 60% to 98.8% by weight of a polyolefin; (B) 0.1% to 30% by weight of at least one compatibilizer; (C) 0.05% to 20% by weight of an amino resin; and (D) 0% to 5% by weight of at least one additive, wherein the amounts of (A), (B), (C) and (D) are based on the total weight of (A)+(B)+(C)+(D), the total weight being 100%, as printing plate in an extrusion-based additive manufacturing process, to an extrusion-based additive manufacturing process comprising a step of selectively depositing a molten thermoplastic material (P) on the film or sheet and to a 3D printing kit comprising a thermoplastic material (P) suitable for extrusion-based additive manufacturing and a printing plate comprising the film or sheet.

IPC Classes  ?

• B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins
• B33Y 10/00 - Processes of additive manufacturing
• C08L 23/12 - Polypropene

Abstract

The invention relates to a method for determining a concentration of a target gas in the blood of a living human being or animal. For this purpose, the method according to the invention has the steps of: generating electromagnetic excitation radiation with a carrier frequency, said carrier frequency being selected such that the target gas and an absorption gas absorb the excitation radiation; modulating an amplitude or the carrier frequency of the excitation radiation with a modulation frequency; superficially illuminating an absorption section of the skin of the living being with the excitation radiation; generating a sound wave by means of the absorption of the excitation radiation in the absorption gas; and detecting at least one amplitude or a phase of the sound wave as a measurement of a concentration of the target gas on the absorption section. The invention additionally relates to a photoacoustic sensor for determining a concentration of a target gas in the blood of a living human being or animal.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

A sensor array comprises a base for providing a probe signal and a plurality of modular recording sites. Each modular recording site of the plurality of modular recording sites is configured for receiving a signal, for converting the signal into a digital sensor signal using an in-situ analog-to-digital converter and to provide the digital sensor signal to the base using a communication interface. The communication interfaces of the plurality of modular recording sites are connected serially with respect to each other and to the base and each in-situ analog-to-digital converter is configured for operating in a first operating mode and in a second operating mode. The base is configured for receiving a plurality of digital sensor signals from the plurality of modular recording sites and to process the plurality of digital sensor signals so as to provide the probe signal.

IPC Classes  ?

• A61B 5/262 - Needle electrodes
• A61B 5/293 - Invasive
• A61B 5/302 - Input circuits therefor for capacitive or ionised electrodes, e.g. metal-oxide-semiconductor field-effect transistors [MOSFET]
• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a method for identifying a sequence of monomer units of a biological or synthetic heteropolymer. The invention also relates to the use of a nanopore to identify a sequence of monomer units of a biological or synthetic heteropolymer. The invention also relates to a computer-implemented method, a computer program code and a data-processing system for identifying a sequence of monomer units of a biological or synthetic heteropolymer.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for identifying a sequence of monomer units of a biological or synthetic heteropolymer. The invention also relates to the use of a nanopore to identify a sequence of monomer units of a biological or synthetic heteropolymer. The invention also relates to a computer-implemented method, a computer program code and a data-processing system for identifying a sequence of monomer units of a biological or synthetic heteropolymer.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A microfluidic device for isolation objects from a liquid suspension comprises at least one fluid inlet and at least one fluid outlet, at least one fluid channel fluidically connecting the at least one fluid inlet to the at least one fluid outlet, a plurality of passive hydrodynamic trapping sites arranged along the at least one fluid channel, each trapping site configured to trap a defined number of objects from a liquid suspension flowing along the at least one fluid channel, and a plurality of nozzle channels, wherein each nozzle channel is in fluidic communication with one of the trapping sites and fluidically connects this trapping site with an associated nozzle orifice. A force may be applied concurrently to the trapped objects and the liquid columns in the nozzle channels so that a liquid aliquot containing the defined number of objects is ejected from each nozzle orifice.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• B01L 3/02 - BurettesPipettes

Abstract

The present invention relates to a coil device for magnetic resonance imaging and/or magnetic resonance spectroscopy. The present invention further relates to a coil array of such coil devices. Moreover, the present invention relates to a power supply device for a coil device for magnetic resonance imaging and/or spectroscopy as well as to a signal receiving device for a coil device for magnetic resonance imaging and/or spectroscopy. Furthermore, the present invention relates to an apparatus for magnetic resonance imaging and/or magnetic resonance spectroscopy as well as to a method for performing magnetic resonance imaging and/or magnetic resonance spectroscopy.

IPC Classes  ?

• G01R 33/3415 - Constructional details, e.g. resonators comprising surface coils comprising arrays of sub-coils
• G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver
• G01R 33/34 - Constructional details, e.g. resonators

Abstract

The present invention is directed to a kit of parts having biological activity, the kit of parts comprising a first target comprising a first protein and a second target comprising a second protein, wherein the first protein and the second protein are suitable to form a heterodimer upon irradiation with UV, visible or infrared light in a first wavelength range or in the dark, which can be reversed upon irradiating the heterodimer with UV, visible or infrared light in a second wavelength range or in the dark, wherein the second wavelength range is different from the first wavelength range, wherein the biological activity consists of triggering both the uptake of DNA, RNA, proteins, or small molecules into a cell which is preferably genetically unmodified, and biological effects, and characterized in that at least one of the first and the second target itself has reduced biological activity as compared with the heterodimer.

IPC Classes  ?

• C12N 15/86 - Viral vectors

Abstract

Thauera aromatica 333, 25- hydroxy-7-dehydrocholesterol and analogous alcohols. The underlying biocatalytic method links the water-dependent hydroxylation of alkyl residues with the nitrate- reducing respiratory chain of the strain as electron acceptor system. In contrast to commonly used methods, the present method does no longer require the artificial regeneration of the electron-carrier.

IPC Classes  ?

• C12P 33/06 - Hydroxylating
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The invention relates to a SAW device (1) comprising a substrate (2) and at least one piezoelectric layer (3), arranged on the substrate, and at least one transducer (4), arranged on the piezoelectric layer (3), wherein the substrate (2) and the piezoelectric layer (3) each contain or consist of a material which forms a whorled crystal system and the substrate (2) has at least a first side (21), which is oriented in the r plane (1102), and the piezoelectric layer (3) has at least a first side (31), which is oriented in the a plane (1120), wherein the first side (21) of the substrate (2) and the first side (31) of the piezoelectric layer (3) are arranged approximately parallel to one another and the transducer (4) contains or consists of at least one metal layer which comprises a plurality of contact fingers (45) of which the length (l) is in each case greater than the width (b) and of which the longitudinal direction (l) forms an angle φ of approximately 40° to approximately 80° with the c axis of the piezoelectric layer (3). The invention also relates to a method for the operation of such a SAW device (1) and to the use thereof.

IPC Classes  ?

• H03H 9/02 - Networks comprising electromechanical or electro-acoustic elementsElectromechanical resonators Details

Abstract

The present invention is inter alia concerned with a T cell receptor fusion construct comprising two specific peptidic moieties, one of these two moieties binding to the spike protein from coro- naviruses and binding to ACE2, in particular the spike proteins from SARS-CoV-2 and/or SARS- CoV-1, and one of these moieties being a protein of the T cell receptor complex. A vector comprising the genetic information encoding the T cell receptor fusion construct is also part of the present invention, as well as a process of transfecting or transducing T cells and a modified T cell comprising the T cell receptor fusion construct. Importantly, the present invention also relates to a T cell receptor fusion construct, a vector or a modified T cell for use in the treatment of a disease and in particular for use in the treatment of a disease caused by a coronavirus such as e.g. COVID-19 or SARS.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

The present invention relates to a compound or pharmaceutically acceceptable salts thereof, that modulates NLRP3 in that the NLRP3 inflammasome is activated. This invention further relates to the compounds and/or compositions for use in the prevention and treatment of a condition, disease or a disorder by activating the NLRP3 inflammasome, wherein the disease is selected from a group comprising infectious diseases, or cancer. Moreover, the invention relates to the use of the present compounds for analyzing the activity of NLRP3 activation.

IPC Classes  ?

• A61K 31/4245 - Oxadiazoles
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

The present invention relates to a multiple solar cell (1) having at least two partial cells (2, 3), at least one partial cell (2, 3) being formed from a direct semiconductor, and having an upper partial cell (2) facing the light and a lower partial cell (3) facing away from the light, an upper bandgap of the upper partial cell (2) being greater than a lower bandgap of the lower partial cell (3), and an intermediate layer (4) being arranged on the side of the lower partial cell (3) facing away from the light. The invention is distinguished in that an optical element (5) comprising a lower mirror element (6) is arranged on a side of the intermediate layer (4) that faces away from the light, the optical element (5) comprising a partial element (7) having a plurality of structure elements (8) which are arranged in a lateral direction (15) directly or indirectly on the side of the intermediate layer (4) facing away from the light, and in that the partial element (7) and the lower mirror element (6) are formed from an identical material and the structure elements (8) have a mean spacing (X) less than or equal to 1.3-times a distance value (A), the distance value (A) arising from a ratio of a wavelength assigned to the lower bandgap to a refractive index of the lower partial cell (3), or in that the lower mirror element (6) is formed as a plane mirror with a roughness with an effective value of less than 50 nm, preferably less than 20 nm, with at least one separation layer (9) being formed between the partial element (7) and the lower mirror element (6).

IPC Classes  ?

• H01L 31/056 - Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means the light-reflecting means being of the back surface reflector [BSR] type
• H01L 31/0687 - Multiple junction or tandem solar cells
• H01L 31/0693 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PN homojunction type, e.g. bulk silicon PN homojunction solar cells or thin film polycrystalline silicon PN homojunction solar cells the devices including, apart from doping material or other impurities, only AIIIBV compounds, e.g. GaAs or InP solar cells

Abstract

The present invention provides the use of a CASP8AP2 antagonist in the prevention or treatment of cancer. Preferably, the antagonist reduces the viability of the cancer cells without significantly reducing the viability of normal cells in the subject to be treated. Further, methods of treatment and pharmaceutical compositions suitable in said methods are provided, as well.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to circular DNA molecule for rescuing recombinant adenoviruses comprising a recombinant adenoviral genome with two inverted terminal repeats (ITRs) flanking the genome ends, wherein at least one of the ITRs is associated with a target sequence adjacent to a PAM sequence, wherein the target sequence is configured for generating an RNA-guided DNA endonuclease-mediated DNA double strand break at the external end of or in close proximity outside the external end of the respective ITR, preferably within less than about (15) nucleotides. The invention also relates to a kit and a method for rescuing recombinant adenoviruses comprising or using a circular DNA molecule as described herein.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The invention relates to a mouse double minute 2 (MDM2) inhibitor for use in the treatment and/or prevention of a hematologic neoplasm relapse after hematopoietic cell transplantation (HCT) in a patient. In embodiments, the hematologic neoplasm is a leukaemia, preferably acute myeloid leukaemia (AML). Preferably, the patient received an allogeneic T cell transplantation, either together with the HCT and/or after HCT, such as at the time point of MDM2 administration. Furthermore, the invention relates to a pharmaceutical composition comprising a MDM2 inhibitor and an exportin 1 (XPO-1) inhibitor for use in the treatment and/or prevention of a hematologic neoplasm relapse after hematopoietic cell transplantation (HCT) in a patient according to any of the preceding claims.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to modified Cas9 nuclease comprising a substantial part of a Cas9 nuclease and fused thereto at least one substantial part of a dominant negative effector on non-homologous end-joining selected from the group consisting of RNF168, 53BP1, Ku80 and DNA-PK which compete with NHEJ promoting factors and CtIP.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 19/00 - Hybrid peptides
• C12N 9/22 - Ribonucleases
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to modified Cas9 nuclease comprising a substantial part of a Cas9 nuclease and fused thereto at least one substantial part of a dominant negative effector on non-homologous end-joining selected from the group consisting of RNF168, 53BP1, Ku80 and DNA-PK which compete with NHEJ promoting factors and CtIP.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 19/00 - Hybrid peptides
• C12N 9/22 - Ribonucleases
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to a method and a kit to detect the presence or absence of at least two different target molecules form one sample, wherein at least one target molecule is a target analyte of interest and at least one other target molecule is a target nucleic acid of interest, wherein the method combines performing an isothermal amplification reaction, wherein the target nucleic acid or its amplicon is labeled with at least two affinity labels and a ligand binding assay, wherein affinity molecules are used, which can capture and detect the presence of target analytes and/or labeled target nucleic acid via signal generation. The invention also relates to the use of this method or kit in various fields.

IPC Classes  ?

• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates

Abstract

An architecture for classification of a decision tree ensemble comprises a rank computing block (1) and a tree processing block (2). The rank computing block (1) comprises one computation unit (10) per feature fi to be classified, wherein each computation unit (10) comprises a memory (11) and a logic (12). The memory (11) is configured to save threshold values of the trees in the decision tree ensemble, wherein the memory is arranged to save the threshold values in one group per feature to be classified. The threshold values in a group are sorted according to a threshold index. The logic (12) is arranged to conduct a node comparison of the threshold values of a corresponding group of threshold values and output a rank of as a result of said comparison, wherein a rank represents an encoded address to access said threshold value. The tree processing block (2) comprises one tree processing unit (20) per tree in the decision tree ensemble and each processing unit is configured to determine a class of the feature fi to be classified as a function of ranks.

IPC Classes  ?

• G06N 5/00 - Computing arrangements using knowledge-based models
• G06N 20/20 - Ensemble learning

Abstract

The present invention provides novel PSMA targeting urea-based ligands that binds to prostate?specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.

IPC Classes  ?

• A61K 51/04 - Organic compounds

Abstract

The present invention provides novel PSMA targeting urea-based ligands that binds to prostate‐specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 101/02 - Halogens
• A61K 103/00 - Radioactive metals

Abstract

A computer-implemented method for multimodal egocentric future prediction in a driving environment of an autonomous vehicle (AV) or an advanced driver assistance system (ADAS) equipped with a camera and comprising a trained reachability prior deep neural network (RPN), a trained reachability transfer deep neural network (RTN) and a trained future localization deep neural network (FLN) and/or a trained future emergence prediction deep neural network (EPN).

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 3/08 - Learning methods

Abstract

An adjustment aid includes a first adjustment electrode assembly having an excitation electrode and an evaluation electrode, a second adjustment electrode assembly having a reception electrode and a transmission electrode, and a control and evaluation circuit connected to the first adjustment electrode assembly. The first adjustment electrode assembly is arranged on the first component. The second adjustment electrode assembly is arranged on the second component. The control and evaluation circuit supplies the excitation electrode with an excitation signal and taps a measurement signal at the evaluation electrode. The measurement signal depends on a degree of overlap between the first adjustment electrode assembly and the second adjustment electrode assembly.

IPC Classes  ?

• A61N 1/37 - MonitoringProtecting

Abstract

The present invention relates to a compound according to formula (I) Formula (I) a physiologically acceptable salt, a solvate, or a hydrate thereof for use in the prevention and/or treatment of diseases caused by betacorona-virus infection in a mammalian subject, such as a human, wherein said compound is administered by inhalation as a pharmaceutical composition comprising preferably alcohol as a carrier. A preferred example is viral infection caused by SARS.

IPC Classes  ?

• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A transurethral bladder catheter (1) is proposed which permits removal of urine from the bladder and also timed and portion-controllable photodynamic therapy for killing bacterial microbes within the bladder and which allows further liquids to be delivered in a controlled manner in order to perform irrigation or other therapies. This is achieved by a stopper (5) which can be plugged in at the distal end of the secondary lumen (3) of the catheter (1) and on which, at one side, a dosing dispenser (7) and a switchable and/or controllable current source (12) are attached, and on which, at the other side, a lighting means is located. The stopper (5) has a feed-through for a current cable (10) and a through-channel (6) which is connected to the dosing dispenser (7). The length of the current cable (10) including the lighting means is the same as that of the secondary lumen (3).

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61M 25/00 - CathetersHollow probes

Abstract

The invention relates to a method of amplifying DNA of more than one samples for generating a sequencing library, the method comprising a.) providing for each of the more than one samples an individual reaction vessel comprising the DNA in single stranded form, b.) adding first primers to the reaction vessel to produce a reaction mixture, wherein the first primers comprise in a 5' to 3' orientation a constant sequence and a variable sequence, wherein the constant sequence comprises in a 5' to 3' orientation a first part with a sequence that can be common for the more than one samples and a second part with a sequence that is different for each of the more than one samples, c.) adding a DNA polymerase to the reaction vessel, d.) subjecting the reaction mixture to a temperature at which the first primers anneal to the single stranded DNA via the variable sequence, e.) subjecting the reaction mixture to a temperature at which the DNA polymerase extends the 3'-ends of the annealed first primers to produce first-round amplicons, f.) subjecting the reaction mixture to a temperature to produce single stranded amplicons, g.) subjecting the reaction mixture to a temperature at which free first primers anneal to the single stranded DNA and to the first-round amplicons via the variable sequence, h.) subjecting the reaction mixture to a temperature at which the DNA polymerase extends the 3'-ends of the annealed first primers to produce first-round amplicons from first primers annealed to the provided DNA and second-round amplicons from first primers annealed to first-round amplicons, i.) subjecting the reaction mixture to a temperature to produce single stranded amplicons, repeating the steps (g)-(i) to produce second-round amplicons of the provided DNA.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The present invention relates to a method for isolating one or more molecule fractions from a sample, the method comprising: (i) introducing the sample into a separation unit; (ii) in a separation channel of the separation unit, which channel is filled with a separation medium, separating molecules contained in the sample into molecule fractions; (iii) extracting one or more molecule fractions from an extraction region of the separation channel by activating a metering unit, wherein the extraction region is fluidically coupled to an opening, and by activating the metering unit, medium located in the extraction region is pushed out of the opening as medium fraction, wherein the medium fraction may comprise a molecule fraction or parts thereof.

IPC Classes  ?

• B01L 3/02 - BurettesPipettes
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

30 hydrocarbon radical is used as a catalyst support.

IPC Classes  ?

• C08F 4/02 - Carriers therefor
• C08F 4/6592 - Component covered by group containing a transition metal-carbon bond containing at least one cyclopentadienyl ring, condensed or not, e.g. an indenyl or a fluorenyl ring
• B01J 21/02 - Boron or aluminiumOxides or hydroxides thereof
• C08F 4/52 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides selected from boron, aluminium, gallium, indium, thallium, or rare earths
• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The invention relates to an assembly for optically preconditioning an optically activable biological sample, which comprises a plurality of cells suspended in a liquid, the assembly comprising: a reservoir, which stores the sample and from which the sample can be conveyed through a hollow channel by means of a conveying unit, along which hollow channel the cells can be conveyed serially one after the other and along which hollow channel a light application unit is arranged, which light application unit applies light, with a controllable light application intensity and light application duration, to the cells contained in the sample and flowing through the hollow channel at a flow speed that can be set by means of the conveying unit; and a cell analysis and/or sorting apparatus, which is fluidically connected to the hollow channel downstream of the hollow channel.

IPC Classes  ?

• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 21/64 - FluorescencePhosphorescence
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention concerns new approaches for the diagnosis and treatment of dementia diseases. In particular, the present invention pertains to new markers for diagnosing dementia diseases as well as to new targets for the treatment of dementia diseases.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to Losartan for use in the treatment of a fibrotic disease, characterized in that a dose of 0.4-1.4 mg/kg body weight of the human patient is administered daily, whereby the fibrotic disease is epidermolysis bullosa.

IPC Classes  ?

• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Abstract

in vivoin vivo alone or in combination with pharmaceutical drugs, such chemotherapies, biopharmaceutical drugs, such as antibodies, or small-molecule drugs, such as protein kinase inhibitors.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors

Abstract

A device for the enucleation of intracorporeal tissue regions, in particular of the prostate, is described, having a probe at whose distal end at least one freely accessible electrode body is mounted to which electrical energy can be applied via at least one electrical line running in the longitudinal extent of the probe. The invention is characterized in that the electrode body has a dome-shaped electrode surface and has cross-sectional surfaces which are oriented orthogonally to the longitudinal extent of the probe and whose surface areas along a first axial portion, which contains the distal dome end of the electrode body, increase continuously as the distance from the distal dome end increases, and in that the cross-sectional surfaces are each delimited by a peripheral edge, which is continuously differentiable at each location. The invention is further characterized in that the probe, including the electrode body, has a mechanically stable design, such that pressure and bending forces can be transmitted by means of the probe to the tissue that is to be separated.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

The present invention concerns new approaches for the diagnosis and treatment of dementia diseases. In particular, the present invention pertains to new markers for diagnosing dementia diseases as well as to new targets for the treatment of dementia diseases.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids